Moderna Cancer Vaccine Trial Success Sends Stock Soaring

Moderna and Merck's cancer vaccine, intismeran autogene, has achieved significant success in a Phase 3 trial for high-risk melanoma patients. The therapy, administered with Keytruda, showed improved recurrence-free and distant metastasis-free survival rates.

The positive results sparked a sharp rally in Moderna's share price, surging by around 177% on the day of the announcement. Merck also reached an all-time high following the update.

However, investors are aware that Moderna operates with significant financial losses and manufacturing challenges. The company reported a net loss of $782 million in its second-quarter 2026 results.